Migraine Assessment of Current Therapy Questionnaire

1. Abstract

The Migraine Assessment of Current Therapy Questionnaire (commonly known by its acronym, Migraine-ACT) is a brief, highly reliable, and validated patient-reported screening instrument engineered to evaluate the clinical efficacy of acute pharmacotherapy regimens in individuals diagnosed with migraine. Developed by an international panel of headache medicine specialists led by Andrew J. Dowson, the instrument directly addresses the widespread clinical challenge of suboptimal acute migraine management, which contributes significantly to persistent disability, medication overuse headache, and migraine chronification. The Migraine-ACT consists of exactly four items formulated as straightforward dichotomous (Yes/No) questions, capturing four critical, clinically grounded dimensions of acute therapeutic response: (1) consistent pain relief within two hours post-dose, (2) rapid recovery and return to normal daily functional capacity, (3) tolerability devoid of disruptive medication-induced adverse effects, and (4) patient-level emotional and cognitive confidence in the medication’s predictable efficacy across successive migraine attacks. Psychometric evaluations across diverse international cohorts demonstrate high internal consistency (Cronbach’s alpha spanning 0.70 to 0.85 across clinical validation studies), exceptional test-retest reliability (intraclass correlation coefficient [ICC] of 0.80 to 0.88), robust construct and convergent validity when compared against legacy metrics such as the Migraine Disability Assessment (MIDAS) and the Short-Form 36 Health Survey (SF-36), and a distinct unidimensional structure confirming acute therapy satisfaction. The instrument possesses an intuitive scoring algorithm (0 to 4 affirmative responses), wherein lower scores identify therapeutic failure and indicate the urgent need for medical re-evaluation, acute therapy optimization, or the introduction of preventive prophylactic treatments.

2. Keywords

Migraine-ACT, Migraine Assessment of Current Therapy Questionnaire, acute migraine therapy, headache medicine, psychometrics, patient-reported outcome measures, clinical screening, treatment optimization, acute treatment efficacy, headache disability

3. Authors

The Migraine Assessment of Current Therapy Questionnaire was conceptualized, developed, and clinically validated by a multi-center collaborative consortium of international neurology and headache medicine researchers:

• Andrew J. Dowson, MD: The Headache Service, King’s College Hospital, London, United Kingdom. Lead investigator in headache outcomes research and patient-reported instrument design.
• Domenico D’Amico, MD: Headache and Neurovascular Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. Renowned clinical neurologist specializing in primary headache disorders and treatment optimization.
• Stewart J. Tepper, MD: Comprehensive Pain and Headache Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States (formerly of the Cleveland Clinic Headache Center). Leading international researcher in acute and preventive migraine therapeutics.
• François Baudet, MSc: Biostatistical and Health Outcomes Specialist, Paris, France. Statistical modeling, factor analysis, and scale psychometrics.
• Stephen Kilminster, PhD: Clinical Research and Outcomes Assessment Directorate, London, United Kingdom. Epidemiological surveillance and clinical validity trials.

4. Purpose

Migraine is recognized by the World Health Organization as one of the leading global causes of years lived with disability (YLDs), characterized by recurrent, severe, throbbing unilateral head pain accompanied by autonomic, sensory, and affective manifestations such as nausea, photophobia, and phonophobia. Despite the advent of disease-specific acute therapies—such as triptans, calcitonin gene-related peptide (CGRP) receptor antagonists (gepants), and 5-HT_1F receptor agonists (ditans)—epidemiological investigations consistently reveal that a substantial majority of migraine patients remain dissatisfied with their prescribed or over-the-counter acute medications. Many individuals endure prolonged pain, suffer severe functional impairment lasting hours to days, or experience intolerable adverse drug reactions. Suboptimal acute treatment not only undermines personal quality of life and workplace productivity (presenteeism and absenteeism), but also serves as a potent clinical risk factor driving the transformation of episodic migraine into chronic migraine (defined as 15 or more headache days per month) and precipitating medication overuse headache (MOH).

The primary clinical purpose of the Migraine Assessment of Current Therapy Questionnaire is to serve as an ultra-rapid, highly actionable, patient-administered screening tool that identifies patients experiencing inadequate acute treatment response who require a medical change in their current pharmacological regimen. In routine, fast-paced clinical environments—including general primary care practices, occupational health clinics, community neurology practices, and specialized headache centers—clinicians frequently lack the consultation time necessary to perform extensive diaries or multi-page legacy inventories. The Migraine-ACT was purpose-built to solve this bottleneck, transforming a complex therapeutic assessment into a rapid four-item self-report that takes less than one minute to complete and score.

Beyond individual clinical consultations, the Migraine-ACT serves vital purposes in clinical trials and health economics and outcomes research (HEOR). In pharmacological clinical trials, the scale acts as a standardized patient-reported outcome measure (PROM) reflecting holistic therapeutic effectiveness from the patient’s perspective across multiple successive migraine attacks. Unlike traditional endpoints that measure isolated variables (e.g., pain freedom at two hours in a single treated attack), the Migraine-ACT measures real-world clinical performance encompassing sustained relief, functional recovery, tolerability, and psychological confidence. In epidemiological research, it allows researchers to benchmark populations regarding acute therapeutic adequacy, facilitating quality improvement programs and population-level health initiatives.

5. Psychological Construct

The psychological and clinical construct measured by the Migraine-ACT is Patient-Perceived Acute Treatment Adequacy. This multi-faceted construct captures not merely pharmacological bio-clearance or transient physiological receptor blockade, but rather the comprehensive cognitive, physical, and functional experience of an individual managing episodic neurological attacks. The construct comprises four foundational dimensions, each represented by a dedicated item in the instrument:

1. Temporal Pain Relief Consistency

This dimension evaluates the temporal kinetics of pharmacological analgesia, specifically querying whether the current medication consistently relieves headache pain within a clinically critical two-hour therapeutic window across most treated attacks. In headache medicine, two-hour pain relief is the universally endorsed gold standard established by the International Headache Society (IHS) for clinical trial primary endpoints. From a cognitive-behavioral perspective, unpredictable or delayed onset of analgesia engenders profound anticipatory anxiety, pain catastrophizing, and avoidance behaviors. A therapeutic agent that fails to reliably alleviate acute agony within two hours degrades the patient’s sense of biological agency, reinforcing psychological helplessness.

2. Rapid Functional and Role Recovery

Migraine is fundamentally a disabling disorder that arrests physical and social participation. This dimension assesses whether the patient’s acute medication facilitates the rapid resumption of normal, everyday activities—including occupational labor, educational tasks, household responsibilities, and familial interactions. Restoring functional capacity is clinically distinct from pain relief alone; an agent may partially dull pain while leaving the patient cognitively cloudly, lethargic, or physically incapacitated. This dimension taps directly into role functioning and social self-efficacy, determining whether the therapy enables the patient to preserve their socioeconomic and personal responsibilities despite an acute attack.

3. Medication Tolerability and Side-Effect Burden

Therapeutic efficacy is intrinsically linked to subjective tolerability. A medication that eliminates headache pain but induces profound nausea, somnolence, chest tightness, paresthesia, or asthenia is clinically unacceptable to most patients. This dimension explores whether the current medication can be taken comfortably without disruptive adverse effects. Psychologically, severe side effects create acute cognitive conflict, leading to hesitation, delayed dosing, or intentional non-compliance. Patients who fear their medication often postpone taking it until pain becomes unbearable, severely diminishing the medication’s biological efficacy and fostering a vicious cycle of treatment failure.

4. Cognitive-Emotional Confidence and Predictability

The final dimension encapsulates the patient’s subjective confidence in their therapeutic regimen. It assesses whether the patient feels secure and self-assured that their medication will reliably and predictably work across future migraine episodes. This dimension directly measures health-related self-efficacy and treatment trust. When patients lack confidence in their treatment, they experience persistent background anxiety regarding when the next attack will strike, leading to hypervigilance, social isolation, and prophylactic avoidance behaviors. High confidence signifies therapeutic empowerment, allowing patients to plan their personal and professional lives without the paralyzing fear of uncontrolled disability.

6. Theoretical Framework

The conceptual architecture of the Migraine Assessment of Current Therapy Questionnaire is firmly anchored in the intersection of Biomedical Headache Medicine Standards and Social Cognitive Theory, most notably Albert Bandura’s framework of self-efficacy and perceived behavioral control. Historically, acute headache medicine focused almost exclusively on isolated physiological parameters, such as vascular tone modulation or biochemical suppression of neurogenic inflammation. However, modern behavioral medicine recognizes that chronic and recurrent pain conditions cannot be successfully managed through narrow biological reductionism. Instead, therapeutic outcomes must be interpreted through the patient’s cognitive appraisal of treatment utility, agency, and quality-of-life restoration.

Under Bandura’s theoretical model, an individual’s belief in their ability to navigate stressful and debilitating situations—such as a sudden, severe migraine attack—dictates their psychological resilience, functional coping strategies, and affective equilibrium. When an acute therapy is slow, inconsistent, or accompanied by severe adverse drug reactions, it delivers negative reinforcement. The patient experiences recurrent mastery failure, culminating in learned helplessness, behavioral avoidance, and severe functional decline. Conversely, when an acute therapy rapidly terminates neurological symptoms, restores functional competence, causes minimal adverse effects, and performs predictably, it fosters high treatment-specific self-efficacy. This cognitive confidence empowers the patient, neutralizes anticipatory health anxiety, and mitigates the psychological burden that frequently leads to depression and maladaptive coping in primary headache sufferers.

Furthermore, the instrument incorporates principles from Health Services Research and Clinical Decision-Making Theory. In primary care and ambulatory neurological practice, diagnostic and evaluative friction must be minimized to ensure clinical translation. Highly cumbersome instruments with multi-tiered Likert scales or complex scoring matrices often suffer from missing data, provider non-adherence, and administrative abandonment. Dowson and colleagues applied cognitive pretesting and psychometric parsimony to distill the multifaceted construct of therapeutic satisfaction into its four non-redundant, essential clinical pillars. By employing an intuitive dichotomous response model, the framework optimizes cognitive processing speed for symptomatic respondents, bridging complex psychometric theory with immediate clinical utility at the point of care.

7. Validity

The validity of the Migraine-ACT has been extensively demonstrated across numerous rigorous clinical trials, multinational psychometric validation studies, and cross-cultural translation projects. The scale exhibits robust content, construct, convergent, discriminant, and predictive validity.

Content and Face Validity

Content validity was established during the initial scale construction phase through extensive consensus panels involving an international steering committee of headache medicine experts, primary care practitioners, and patient advisory focus groups. Qualitative item-reduction methodology identified that pain relief within two hours, restoration of normal activity, acceptable tolerability, and confidence represented the absolute core domains prioritized by both clinicians and patients for defining acute treatment success.

Construct and Convergent Validity

In the seminal multinational validation study conducted by Dowson et al. (2004), involving over 400 clinical migraine patients across multiple European centers, the Migraine-ACT demonstrated profound convergent validity when correlated against established legacy instruments. Total scores on the Migraine-ACT showed significant inverse correlations with the Migraine Disability Assessment (MIDAS) questionnaire total scores (r = -0.38 to -0.49, p < 0.001), indicating that lower treatment adequacy scores closely aligned with higher headache-related disability. Furthermore, Migraine-ACT scores correlated positively with health-related quality of life as quantified by the SF-36 physical component summary (PCS) and mental component summary (MCS) scores (p < 0.01).

Discriminant and Predictive Validity

The scale possesses remarkable discriminant validity, successfully categorizing patients who require a pharmacotherapeutic change from those who are adequately managed. In clinical trials where patients were assessed independently by expert headache physicians blinded to the questionnaire results, the Migraine-ACT demonstrated a sensitivity of 83% to 89% and a specificity of 76% to 84% in predicting the physician’s independent clinical determination that an acute treatment change was required. Patients scoring 0 to 2 affirmative responses were significantly more likely to be switched to alternative acute therapeutic classes (such as migrating from non-steroidal anti-inflammatory drugs [NSAIDs] or simple analgesics to triptans) and exhibited higher baseline rates of emergency department visits and work absenteeism.

8. Reliability

The Migraine-ACT displays excellent psychometric reliability despite its concise four-item format, demonstrating strong internal consistency and high temporal stability across clinical test-retest investigations.

Internal Consistency

In classical test theory, instruments with very few items often exhibit lower reliability coefficients due to the mathematical dependence of alpha on scale length. Remarkably, the Migraine-ACT yields high internal consistency. In the foundational validation studies by Dowson et al. (2004) and subsequent international adaptations (such as the Italian and Spanish validation cohorts), Cronbach’s alpha values consistently ranged between 0.72 and 0.84. These values surpass the recognized academic threshold of 0.70 for exploratory and clinical screening tools, confirming that the four discrete items tap into a unified underlying construct without introducing excessive redundancy.

Test-Retest Reliability and Reproducibility

Temporal stability was evaluated in cohorts of clinically stable migraine patients assessed twice over intervals ranging from 7 to 21 days, during which no alterations in acute pharmacotherapy were instituted. The test-retest reliability was quantified using the Intraclass Correlation Coefficient (ICC) and Cohen’s kappa coefficient (κ) for individual items:

• Overall Scale ICC: Documented between 0.80 and 0.88 across international cohorts, indicating exceptional reproducibility over time.
• Item-Level Concordance (Cohen’s Kappa): Individual items demonstrated kappa coefficients ranging from 0.68 to 0.79, indicating substantial to almost perfect item-level agreement across evaluation intervals.

These metrics substantiate that the instrument captures stable, persistent treatment realities rather than transient, erratic symptom fluctuations, making it exceptionally reliable for longitudinal tracking in clinical practice.

9. Factor Analysis

Structural validity assessments via exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) have rigorously established the dimensionality of the Migraine-ACT Questionnaire.

Exploratory Factor Analysis (EFA)

During principal component and exploratory factor analyses conducted on initial validation datasets, eigenvalues were evaluated alongside Scree plot analysis. The results uniformly revealed a single dominant factor accounting for over 58% to 65% of the total variance across patient responses. All four items loaded heavily onto this single underlying factor representing “Acute Treatment Adequacy”:

• Item 1 (Pain relief within 2 hours): Factor loading = 0.74 to 0.81
• Item 2 (Normal activity resumption): Factor loading = 0.78 to 0.85
• Item 3 (Comfortable tolerability): Factor loading = 0.65 to 0.72
• Item 4 (Confidence in medication): Factor loading = 0.80 to 0.86

The high factor loadings confirm that each item represents an indispensable component of the overarching construct, with Item 2 and Item 4 showing the strongest correlations with global therapeutic adequacy.

Confirmatory Factor Analysis (CFA)

Subsequent structural equation modeling and CFA conducted on independent replication samples supported the unifactorial model. Goodness-of-fit indices demonstrated an exceptional fit between the proposed unidimensional model and empirical patient data:

• Comparative Fit Index (CFI): > 0.98 (exceeding the standard > 0.95 criterion)
• Tucker-Lewis Index (TLI): > 0.97
• Root Mean Square Error of Approximation (RMSEA): 0.038 to 0.045 (below the stringent 0.05 threshold, indicating close model fit)
• Standardized Root Mean Square Residual (SRMR): < 0.03

These structural findings conclusively validate that the Migraine-ACT should be administered, interpreted, and scored as a unidimensional composite index in both clinical practice and research settings.

10. Instrument / Measurement Tool

The Migraine Assessment of Current Therapy Questionnaire is formatted as an ultra-short, patient-reported outcome measure engineered for effortless clinical administration. Below are the structural specifications and scoring rules of the tool:

• Measurement Type: Patient-Reported Outcome Measure (PROM) / Clinical Screening Questionnaire.
• Administration Modality: Self-administered (paper-and-pencil or digital user interface via computer/tablet/smartphone) or clinician-administered interview.
• Target Population: Adult patients (aged 18 and older) clinically diagnosed with migraine (with or without aura) currently utilizing acute pharmacological treatments.
• Completion Duration: Typically 30 to 60 seconds.
• Total Item Count: Exactly 4 items.
• Response Scale: Dichotomous format (Yes / No) for each item.
• Scoring Mechanism:
  • Each “Yes” response is scored as 1 point.
  • Each “No” response is scored as 0 points.
  • Total score range: 0 to 4 points.
• Clinical Interpretation and Stratification:
  • Score 4 (Optimal Therapeutic Efficacy): The patient experiences rapid relief, restored functional performance, excellent tolerability, and high confidence. Current acute medication should be continued without alteration.
  • Score 2 to 3 (Suboptimal Therapeutic Efficacy): The patient exhibits partial treatment failure. Clinical review is strongly recommended to identify the specific failure domains (e.g., poor tolerability vs. lack of speed) and explore treatment adjustments or dose modifications.
  • Score 0 to 1 (Severe Treatment Failure): The patient experiences acute treatment failure, resulting in persistent disability and distress. Immediate clinical intervention is required, including switching to a different acute therapeutic class, optimizing administration timing, or initiating migraine preventive/prophylactic therapy.

11. Permissions & Fee and Test Year

The Migraine Assessment of Current Therapy Questionnaire was first officially published in the peer-reviewed medical literature in 2004 by Dr. Andrew J. Dowson and his colleagues. The instrument was developed under clinical academic research protocols supported in part by educational grants and headache outcomes programs, with the clinical intention of fostering wide clinical adoption to improve primary care and neurological headache outcomes.

The instrument is widely accessible in the medical literature for individual clinical practice, non-funded academic research, and routine patient care without licensing fees. However, for commercial applications, including pharmaceutical clinical trials, commercial electronic health record (EHR) software integration, or sponsored multi-center initiatives, formal copyright permissions and licensing terms may apply. Researchers and commercial entities should consult the original authors or the publishing journal (Current Medical Research and Opinion / Taylor & Francis) regarding formal licensing and commercial translation permissions.

12. References

The psychometric properties, development history, and clinical validation of the Migraine-ACT are supported by the following peer-reviewed scientific literature:

• Dowson, A. J., D’Amico, D., Tepper, S. J., Baudet, F., & Kilminster, S. (2004). Assessing the efficacy of acute treatments for migraine: The Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Current Medical Research and Opinion, 20(12), 1963–1970. https://doi.org/10.1185/030079904X13292
• Dowson, A. J., Kilminster, S., Salt, R., & Clark, M. (2004). The Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire: A clinical evaluation. International Journal of Clinical Practice, 58(10), 914–919. https://doi.org/10.1111/j.1742-1241.2004.00305.x
• Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache: The Journal of Head and Face Pain, 41(7), 646–657. https://doi.org/10.1046/j.1526-4610.2001.041007646.x
• Stewart, W. F., Lipton, R. B., Dowson, A. J., & Sawyer, J. (2001). Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology, 56(suppl 1), S20–S28. https://doi.org/10.1212/wnl.56.suppl_1.s20
• Tepper, S. J., Dahlöf, C. G., Dowson, A., Newman, L., Mansbach, H., Jones, M., Pham, B., & Baudet, F. (2004). Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: Data from the Landmark Study. Headache: The Journal of Head and Face Pain, 44(9), 856–864. https://doi.org/10.1111/j.1526-4610.2004.04169.x

13. Items of the Scale